Robert Jones, MD, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, summarizes the key updates in the treatment options of urothelial cancer. Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Prof. Jones talks about the emerging data on antibody-drug conjugates and also discusses the Phase II KEYNOTE-057 trial (NCT02625961) on the use of pembrolizumab in patients with high-risk non-muscle invasive bladder cancer (NMIBC).